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Abstract
Background: Coronary artery disease is the leading cause of morbidity and mortality in patients
with type 2 diabetes. Screening for asymptomatic coronary artery disease with treatment by means
of revascularization seems to be an appealing option for prevention. The utility of such a strategy
has never been challenged in a randomized trial.
Methods/Design: In the present study a cohort of diabetic patients without any symptoms and
without known coronary artery disease will be screened at two diabetes outpatients services.
Those with intermediate or high risk (equal or greater than 10% according to the Italian risk chart)
will be asked to participate and enrolled. They will be seen and followed in order to provide the
best adherence to medical therapy. Half of the patients will be randomized to undergo an exercise
tolerance testing while the other group will continue to be regularly seen at diabetes outpatients
services. Best medical/behavioral therapy will be offered to both groups. Those patients with a
positive exercise tolerance testing will be studied by coronary angiography and treated according
to the severity of coronary lesions by percutaneous stenting or surgery.
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The objective of the study is to evaluate the efficacy of the screening strategy aimed at
revascularization. A cost-effectiveness analysis will be performed at the end of the follow up.
Discussion: The study will provide useful information about prevention and treatment of diabetic
patients at high risk of coronary events. It will be made clearer if detection of silent coronary artery
disease has to be recommended and followed by treatment. Given the simplicity of the study
protocol, it will be easily transferable to the real world.
Trial registration: (ClinicalTrials.gov): NCT00547872
Background
The association between diabetes and cardiovascular dis-
ease is well established. Prevalence of cardiac ischemic
disease in the general population is between 2 and 4%,
while it reaches 55% among adult diabetic patients [1].
Coronary artery disease is the leading cause of death in
diabetic patients accounting for more than 70% of the
deaths [2,3].
It is well known that patients with type 2 diabetes without
prior myocardial infarction have a similar risk of death
from coronary artery disease as patients without diabetes
with prior myocardial infarction. Diabetes is considered
to be a risk equivalent of coronary artery disease for future
myocardial infarction and cardiovascular death [4].
Given these strong associations, there is clear need to
identify patients with type 2 diabetes who are at risk of
cardiovascular events before the onset of symptoms, pro-
viding that an effective treatment is available [5].
Observational studies reported a higher rate of acute cor-
onary syndromes in diabetic patients with documented
but asymptomatic ischemic coronary artery disease [6].
Nevertheless the hypothesis that revascularization will
reduce this risk has never been challenged in a rand-
omized trial.
Screening for coronary artery disease in asymptomatic
diabetic patients is thus an appealing but still unexplored
concept [7].
According to these observations a screening test should be
aimed at detection of severe blockages of the coronary
arteries that might warrant treatment.
An ideal test suitable for screening should be safe, sensi-
tive, cheap, repeatable and widely available [8]. Exercise
tolerance testing seems close to these ideal characteristics
although its sensitivity is low compared with new diag-
nostic tools available today. On the other hand it does not
deliver radiations, it is cheap and really widely available
[9].
Recommendations about the use of exercise testing as a
screening tool are vague because no clear evidence exists.
The American College of Cardiology acknowledges the
possible value of exercise testing in people with diabetes
who are contemplating an exercise program with a
strength of recommendation IIa [10]. The American Dia-
betes Association suggests exercise testing to diabetic
patients when two other major cardiovascular risk factors
are present (strength of recommendation IIb) [11]. What
to do in case of a positive test it is not known.
U.S. Preventive Task Force states that an "adequately pow-
ered randomized trial of screening exercise tolerance test-
ing compared with management based on traditional risk
factors would greatly  inform clinical decision making"
[12].
Method/Design
General objective
The aim of the study is to evaluate efficacy of screening
and treatment of asymptomatic coronary disease in dia-
betic patients at high risk. Screening is achieved by exer-
cise tolerance testing aimed at revascularization, surgical
or percutaneous.
Primary objective
To assess the effectiveness of screening and treatment of
coronary artery disease on the occurrence of cardiac events
(acute coronary syndromes or cardiac death) in a group of
patients with type 2 diabetes considered at intermediate/
high risk according to the risk chart.
Secondary objective
We will also consider and analyse the impact of screening
and treatment of coronary artery disease on the occur-
rence of symptomatic heart failure. Actually diabetic
patients run a higher risk of developing symptomatic
heart failure especially after an acute coronary syndrome
[13].
Study Design
The aim of the study is to assess whether screening and
treatment of asymptomatic coronary artery disease
reduces risk of cardiac events and cardiac death. A pro-Trials 2009, 10:119 http://www.trialsjournal.com/content/10/1/119
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spective open-label randomized controlled trial comparing
a strategy based on exercise testing aimed at revasculariza-
tion with management based on pharmacological/behav-
ioural treatment of traditional risk factors has been
adopted.
Eligible patients will be randomly assigned (ratio 1:1) to
undergo exercise tolerance testing or to continue to be fol-
lowed by our diabetes outpatients services. Best medical/
behavioral therapy will be offered to both groups. Those
patients with a positive exercise tolerance testing will be
studied by coronary angiography and treated according to
the severity of coronary lesions by percutaneous stenting
or surgery (Figure 1).
Study population
Male and female subjects aged ≥ 50 and < 70 years will be
eligible for the study if they meet the following inclusion
criteria:
Inclusion Criteria
• Clinical diagnosis of type 2 diabetes lasting more
than one year, based on standard diagnostic criteria
(patients on treatment with oral hypoglycaemic agents
or insulin or with fasting plasma glucose > 126 mg/dl
on two occasions) irrespective of diabetes treatment
￿ Cardiovascular risk equal or higher than 10%
according to the Italian risk chart available on Progetto
Cuore website [14,15]
￿ Ability to exercise and willingness to comply with all
study requirements
Exclusion Criteria
￿ Typical symptoms or known coronary artery disease
￿ Known or symptomatic heart failure
￿ Exercise testing or any other stress testing performed
in the last year before the enrolment
￿ Electrocardiogram showing left bundle brunch block
or ST depression greater than 1 mm at baseline
￿ Contraindications to double antiplatelet agents
treatment (history of aspirin allergy, bleeding ten-
dency, gastrointestinal haemorrhage or peptic ulcers
within the last six months, use of anticoagulant ther-
apy, thrombocytopenia)
￿ Chronic use of non-steroideal anti-inflammatory
drugs or steroids
￿ Glomerular filtration rate less than 40 ml/min/
1.73m2 according to MDRD formula [16]
￿ Presence of any life -threatening condition
￿ History of active substance or alcohol abuse within
the last year or major psychiatric disorder
Participating Centres
Eligible patients will be screened and recruited by two
Diabetes outpatients services of Azienda USL di Modena
(located in Modena and Sassuolo).
All of the exercise tolerance testing will be performed at
Nuovo Ospedale Civile Sant'Agostino Estense - Medicina
Cardiovascolare (Modena), results and ECG traces will be
revised by three cardiologists (FT, PG and RM).
Coronary angiographies will be performed at local refer-
ence cardiac catheterization laboratory located in Nuovo
Ospedale Civile Sant'Agostino Estense di Baggiovara by
four expert cardiologists (ST, PM, CC and GD). This is a
high volume procedure laboratory serving as the hub in
our district.
Participant enrolment
All eligible patients will be asked to participate. Once
informed, they will be requested to sign a consent form.
At the first visit they will be given a brochure containing
detailed information about diabetes, hypertension,
atherosclerosis and prevention. All participants will con-
tinue with regular follow ups scheduled by the referral
diabetes outpatients service.
All smokers will be invited to quit. Physical activity and
diet will be encouraged.
At the time of first visit a set of data will be collected:
Personal and clinical data regarding diabetes, cardiovas-
cular risk factors, medications and blood pressure meas-
urements will be collected. Information on laboratory
parameters including lipid profile, serum creatinine,
HbA1c will also be collected. Cardiovascular risk will be
calculated according to the Italian risk chart provided by
Istituto Superiore di Sanità [14].
All this data will be abstracted, reported in ad hoc forms
and centrally collected.
During follow up the occurrence of any clinical event
included in the end-points will be notified and verified
through the registers of local Hospital admissions. After
the completion of follow each patient will be contacted
for the final visit.Trials 2009, 10:119 http://www.trialsjournal.com/content/10/1/119
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DADDY-D Trial Flow Chart Figure 1
DADDY-D Trial Flow Chart.
Diabetes Clinics screen for eligibility of their patients 
and invite them to participate 
Informed consent, data collection 
RANDOMIZATION
Exercise tolerance testing  Treatment of Traditional
Risk Factors
Refuse to participate 
Test negative 
or incomplete Test positive 
Coronary
angiography
No coronary 
stenosis
Coronary
stenosis
Refuse
angiograhy 
Revascularization
FOLLOW UP Trials 2009, 10:119 http://www.trialsjournal.com/content/10/1/119
Page 5 of 7
(page number not for citation purposes)
Randomization
Allocation to screening will be separately determined and
communicated back by e-mail to diabetes services which
will contact patients to schedule exercise testing a few days
after their enrolment.
We chose a stratified block randomization with one to
one allocation ratio. The allocation sequence was gener-
ated through a specific software available on the web [17],
the scheme has been kept concealed.
Patients will be stratified according to age (≥ or < 60 years
old); gender and cardiovascular risk score (≥ or < 20%).
Pharmacological/Behavioural prevention of 
cardiovascular events
Pharmacological/behavioural prevention of cardiovascu-
lar events will be the same in both groups. Experimental
and control group will continue to be followed at our
local Diabetic Clinics that will try to provide maximal
adherence the European Society of Cardiology Guideline
[18] indications about control of hypertension, hypercho-
lesterolemia and glycaemia.
Screening procedures
Patients chosen for screening will be scheduled for exer-
cise testing a few days after their enrolment.
A maximal symptom-limited exercise protocol will be
used with a treadmill (T-2100 Treadmill - GE Healthcare
medical system) according to the standard Bruce protocol.
The test will be performed following the American Heart
Association Guideline [10]. Twelve ECG leads will be
recorded every minute and blood pressure will be meas-
ured manually at rest and every three minutes. Ventilatory
oxygen consumption, expressed in multiples of resting
requirements (METS), will be estimated by exercise dura-
tion.
The exercise test will be defined as maximal if the patient
will reach 80% of the predicted exercise capacity accord-
ing to Gulati formula [19]. Sub maximal tests without
ECG signs and/or symptoms of ischemia will be consid-
ered not diagnostic and will not lead to any other proce-
dure.
The exercise test will be considered positive if showing
horizontal or downsloping ST segment depression of 1
mm or more calculated at 0.06-0.08 second after the J
point at precordial leads (V3-V6).
Coronary angiography will be proposed to all patients
with positive exercise testing.
Coronary angiography will be carried out within 30 days
after the exercise testing. All angiography will be per-
formed at our local reference cath-laboratory.
Coronary artery disease will be defined as being signifi-
cant if lumen stenosis will be greater than 50% at level of
left main or left anterior descending, or greater than 70%
at level of circumflex or right coronary artery.
Treatment will be decided together with two consultant
cardiologists after reviewing coronary anatomy. Treat-
ment (surgery or stenting) will be determined keeping the
European Guideline as a reference guide [18].
Sample Size Estimation
The sample size estimates are based on the following
assumptions:
￿ Follow up for three years
￿ Event rate in screened population: 1.03/year
Based on existing data we can assume that about 80%
patients will test negative [20] and run a risk of 0.97%
per year [21] while the remaining 20% of patients will
test positive running a risk of 1.03% per year after
treatment according to the results of the ACIP trial
[22]. This results in a mean risk of 1.03 per year within
the group.
￿ Event rate in follow up population: 2.6/year
The cardiac event rate reported in over 10000 Italian
diabetic patients without evidence of cardiac disease
was collected by the Italian Istituto Superiore di Sanità
(Diabetes and Informatics Study Group): the cumula-
tive incidence of cardiac events was 2.88% per year in
men and 2.33% per year in women [23].
￿ Two-sided tests of significance at an alpha = 0.05
￿ Power analysis of 0.80
Given these assumptions, the total number of subjects to
be enrolled is of 364 patients for each arm [24].
Statistical analysis
The results will be evaluated based on the intention to
treat analysis.
The incidence rates will be estimated using Kaplan-Meier
survival curves that will be compared using logrank anal-
ysis. The treatment efficacy will be assessed by multivari-
ate analyses using Cox's regression model.Trials 2009, 10:119 http://www.trialsjournal.com/content/10/1/119
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Interim Analyses
During the study interim analyses will be performed every
year with the scope of verifying the correctness of the
assumptions made for sample size estimation with regard
to the primary end point event rate (this information can
influence the duration of follow up) and to avoid unfore-
cast excess of event rate in the treatment group.
Economic evaluation
We will assess the incremental costs and the economic
consequences of screening for asymptomatic coronary
artery disease in diabetic patients with the aim of revascu-
larization compared with usual care alone according to
established methods for the analysis of patient-level data
[25]. We will estimate all health care consumption and
costs of both groups verifying hospital admissions from
hospital records.
Ethical consideration
The study will be conducted in accordance with European
Commission guidelines for Good Clinical Practice and
performed according to the revised Declaration of Hel-
sinki. The study protocol was approved by local Ethical
Committee.
The trial was registered at ClinicalTrial: the U.S. National
Institute of Health registry of federally and privately sup-
ported clinical trials conducted in the United States and
around the world [NCT00547872].
Publication Policy
The study results will be submitted for publication in an
appropriate journal irrespective of the outcome. Trial data
will be reported according to the Consolidated Standards
of Reporting Trials (CONSORT statements) [26]. The
principal investigator will be responsible for timely gener-
ation of report manuscripts, and prior to submission the
co-investigators will review and approve study results.
Timing
September 2007 - Recruitment starts
December 2009 - Recruitment completed
December 2011 - Last participant completes 2-year fol-
low-up
February 2012 - Analysis and publication of 2-year data
December 2012 - Last participant completes 3-year fol-
low-up
February 2013 - Analysis of 3-year data and final publica-
tion
Discussion
The study will be among the first randomised trials to
investigate the effectiveness and cost-utility of a strategy of
screening for unknown coronary artery disease in diabetic
patients aimed at revascularisation. Recently the publica-
tion of DIAD trial results [27] demonstrates that screening
asymptomatic diabetic patients by myocardial perfusion
imaging without any treatment strategy does not affect
outcome. This study cannot be considered the last word in
this field because a screening plan should be performed
only if treatment is available when positive cases are
found. DIAD study design is not thought to test screening
and treatment together but screening alone. Moreover the
screening tool was myocardial perfusion imaging, a very
sensitive and specific test, but with considerable radiation
burden. In case of favourable results such a strategy would
not be applicable to a large population due to costs and
risks. Exercise tolerance testing is a simple and cheap test
with low or no risk, it does not deliver radiations. In case
of positive results the same strategy would be completely
feasible in the real world.
Even the publication of BARI 2D [28] trial results does not
represent the final answer to the dispute. BARI 2D was not
designed as screening trial, patients with left main disease
were excluded and patients with history of heart failure or
ischemic heart disease were included. Furthermore a ben-
efit in terms of major cardiovascular events was observed
in patients undergone coronary artery bypass.
This study is designed as screening and treatment study
and mandate coronary angiography for every patient with
positive exercise testing. In case of coronary blockages,
revascularization (percutaneous or surgical) is proposed.
The results will help to establish if a screening strategy fol-
lowed by revascularization is the best approach to high
risk diabetic patients.
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